Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Brand names: Omvoh
12.1 Mechanism of Action Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is involved in mucosal inflammation and affects the differentiation, expansion, and survival of T cell subsets, and innate immune cell subsets, which represent sources of pro-inflammatory cytokines. Research in animal models has shown that pharmacologic inhibition of IL-23p19 can ameliorate intestinal inflammation. Mirikizumab-mrkz inhibits the release of pro-inflammatory cytokines and chemokines.
Contraindications
9 documented side effects by frequency
No community discussions found for MIRIKIZUMAB-MRKZ yet.
0 available comparisons
No comparisons yet.
Dosage Forms
Tablet
Route
Subcutaneous, Intravenous